ValuEngine upgraded shares of Alimera Sciences, Inc. (NASDAQ:ALIM) from a sell rating to a hold rating in a research note issued to investors on Thursday, July 13th.

Several other analysts also recently issued reports on ALIM. HC Wainwright set a $5.00 price target on shares of Alimera Sciences and gave the company a buy rating in a report on Tuesday, July 11th. Zacks Investment Research raised shares of Alimera Sciences from a sell rating to a hold rating in a research note on Thursday, March 30th. Cowen and Company reissued a buy rating and set a $3.00 price objective on shares of Alimera Sciences in a research note on Tuesday, July 11th. Finally, Rodman & Renshaw assumed coverage on shares of Alimera Sciences in a research note on Thursday, April 27th. They set a buy rating and a $4.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Alimera Sciences has an average rating of Hold and a consensus price target of $3.38.

Alimera Sciences (NASDAQ:ALIM) opened at 1.53 on Thursday. The company’s 50-day moving average price is $1.43 and its 200 day moving average price is $1.39. The stock’s market capitalization is $99.30 million. Alimera Sciences has a 52-week low of $1.03 and a 52-week high of $1.87.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million during the quarter, compared to analysts’ expectations of $10.20 million. During the same period last year, the company earned ($0.17) EPS. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. On average, equities research analysts predict that Alimera Sciences will post ($0.21) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “ValuEngine Upgrades Alimera Sciences, Inc. (ALIM) to “Hold”” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/09/alimera-sciences-inc-alim-upgraded-to-hold-at-valuengine-updated-updated-updated.html.

A number of institutional investors have recently modified their holdings of the company. KCG Holdings Inc. raised its position in shares of Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares during the period. JW Asset Management LLC raised its position in shares of Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares during the period. Finally, Kennedy Capital Management Inc. acquired a new stake in Alimera Sciences during the first quarter valued at about $467,000. 43.58% of the stock is owned by hedge funds and other institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related stocks with our FREE daily email newsletter.